Gold prices tick higher on fresh US tariff threats, Fed rate cut hopes
Investing.com - JPMorgan has reduced its price target on Twist Bioscience (NASDAQ:TWST) to $25.00 from $33.00, while maintaining an Underweight rating on the synthetic biology company. The stock has already declined nearly 13% in the past week, according to InvestingPro data.
The firm acknowledges Twist Bioscience as a leader in the synthetic biology market, noting the company leverages proprietary silicon-based technology to manufacture various synthetic DNA-based products at lower costs and with greater efficiency. While the company maintains strong revenue growth of 23% over the last twelve months, it faces profitability challenges with negative EBITDA of $119 million.
Twist’s product portfolio includes synthetic genes, next-generation sequencing sample preparation kits, and antibody libraries, with future plans for DNA-based data storage solutions.
Despite recognizing Twist as a market leader in an "increasingly attractive niche," JPMorgan views the stock’s risk-reward profile as "skewed to the downside."
The downward price target adjustment comes as JPMorgan cites the stock’s "strong outperformance and premium valuation relative to peers" as key factors in its cautious outlook.
In other recent news, Twist Bioscience reported a notable 18% increase in revenue for Q3 2025, reaching $96.1 million. Despite this growth, the company faced an adjusted EBITDA loss of $8 million, which still marks an improvement from the previous fiscal year. TD Cowen has adjusted its price target for Twist Bioscience to $36, down from $58, while maintaining a Buy rating, citing changes in the company’s fiscal year 2025 guidance due to a key customer’s transition in the Next-Generation Sequencing (NGS) segment. Evercore ISI also lowered its price target for the company to $46 from $50, maintaining an Outperform rating. The firm noted strong performance in the NGS segment and solid gross margin results as contributing factors. These developments reflect ongoing adjustments and expectations in Twist Bioscience’s financial outlook.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.